Iris Najjar

Dr. Iris Najjar

Hôpitaux Universitaires Genève
orcid

Research Focus & Metrics

Academic Career Length

7Years (2020-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 July 2020 in Brain, Behavior, and Immunity
Verified
Journal Article
Closed access
MCMatteo Coen
Matteo Coen
GJGrégoire Jeanson
Grégoire Jeanson
LAL. Alejandro Culebras Almeida
L. Alejandro Culebras Almeida
AHAnnemarie Hübers
Annemarie Hübers
FSFlorian Stierlin
Florian Stierlin
JSJacques Serratrice
Jacques Serratrice

18 February 2020 in Journal of Clinical Medicine
Verified
Journal Article
Open access
PDF file
Iris NajjarIris Najjar
Iris Najjar
FPFlorina Paluca
Florina Paluca
KLKonstantinos Loukidis
Konstantinos Loukidis
PTPhilip Tarr
Philip Tarr
Recurrent Campylobacter enteritis is a well-recorded complication of primary hypogammaglobulinemia but has only rarely been reported with other types of immunodeficiency, and no cases have been reported after rituximab-associated secondary hypogammaglobulinemia. We therefore reviewed our local microbiology laboratory databases and conducted a literature search, to provide a detailed characterization of the immunodeficiency states associated with recurrent Campylobacter enteritis. Published cases had primary hypogammaglobulinemia, most frequently in the setting of common variable immunodeficiency, x-linked agammaglobulinemia, and Good syndrome. No cases were identified in the literature after rituximab or secondary hypogammaglobulinemia. We report a 73-year-old patient with recurrent Campylobacter enteritis and hypogammaglobulinemia in the setting of non-Hodgkin lymphoma, chemotherapy, and maintenance rituximab. Physicians should be aware of the association of recurrent Campylobacter enteritis and immunodeficiency, most commonly in primary hypogammaglobulinemia. Rituximab alone may not be sufficiently immunosuppressive for recurrent campylobacteriosis to occur; additional factors, including hematological malignancy and its treatment, appear necessary. Patients with recurrent Campylobacter enteritis and those starting rituximab should be investigated for hypogammaglobulinemia and B-lymphopenia.

17 January 2022 in BMJ Open
Verified
Journal Article
Open access
PDF file
Iris NajjarIris Najjar
Iris Najjar
JSJennifer Socquet
Jennifer Socquet
AGAngele Gayet-Ageron
Angele Gayet-Ageron
BRBara Ricou
Bara Ricou
JBJulien Le Breton
Julien Le Breton
ENEva Niyibizi
Eva Niyibizi
Objectives: The aim of this study was to determine the prevalence and forms of gender discrimination and sexual harassment experienced by medical students and physicians in French-speaking part of Switzerland. Design and setting: We conducted an online survey using a questionnaire of 9 multiple-choice and 2 open questions between 24 January 2019 and 24 February 2019. Our target population was medical students and physicians working at hospitals and general practitioners from the French-speaking part of Switzerland. The online survey was sent via social media platforms and direct emails. We compared answers between male-determined and female-determined respondents using either χ 2 or Fisher’s exact tests. Results: Among 1071 responders, a total of 893 were included (625 females, 264 males, 4 non-binary and 1 non-binary and male). 178 were excluded because they did not mention their working place or were working only outside Switzerland. Because of the small number of non-binary participants, they were not contemplated in further statistical analysis. Of 889 participants left, 199 (31.8%) women and 18 (6.8%) men reported having personally experienced gender discrimination, in terms of sexism, difficulties in career development and psychological pressure. Among women, senior attendings were the most affected (55.2%), followed by residents (44.1%) and junior attendings (41.1%). Sexual harassment was equally observed among women (19.0%) and men (16.7%). Compared with men (47.0%), women (61.4%) expressed the need to promote equality and inclusivity in medicine more frequently (p<0.001), as well as the need for support in their professional development (38.7% women and 23.9% men; p<0.001). Conclusions: Gender discrimination in medicine in French-speaking Switzerland affects one-third of women, in particular, those working in hospital settings and senior positions.

19 August 2025 in CMI Communications
Verified
Journal Article
Open access
Iris NajjarIris Najjar
Iris Najjar
CSCamila De Paula Siqueira
Camila De Paula Siqueira
ISIngrid Nayara Marcelino Santos
Ingrid Nayara Marcelino Santos
PCPaulo Gustavo Costa
Paulo Gustavo Costa
JSJôiciglecia Pereira Dos Santos
Jôiciglecia Pereira Dos Santos
AGAna Cristina Gales
Ana Cristina Gales

21 November 2025 in International Journal of Antimicrobial Agents
Verified
Journal Article
Open access
Iris NajjarIris Najjar
Iris Najjar
LGLarissa Simão Gandolpho
Larissa Simão Gandolpho
JSJôiciglecia Pereira dos Santos
Jôiciglecia Pereira dos Santos
CSCamila de Paula Siqueira
Camila de Paula Siqueira
IMIkechukwu B. Moses
Ikechukwu B. Moses
AGAna Cristina Gales
Ana Cristina Gales
There has been renewed interest in phages amidst growing antimicrobial resistance. Their potential for intestinal decolonisation is interesting because of their specificity, minimal side effects, and microbiota preservation. In addition, phage-resistant bacterial mutants that arise during treatment may become more susceptible to antibiotics and less virulent, possibly leading to better clinical outcomes. This study's primary objective is to measure the efficacy of phage-based intestinal decolonisation of Klebsiella pneumoniae carbapenemase (KPC)-producing K. pneumoniae (KPC-Kp) at 14 days post-treatment, as well as its feasibility, which is defined as >80% achieving at least 7 days of treatment. Secondary objectives will include phage safety at 14 days post-treatment, intestinal KPC-Kp load changes over time, characterisation of phage-resistant KPC-Kp mutants, microbiome changes, infection-related outcomes, and general clinical outcomes 3 months after the end of treatment. This feasibility and proof-of-concept study aims to include 15 high-risk patients recruited from a tertiary hospital in São Paulo who will receive individualised phage combinations for a mean duration of 14 days. Safety data will be reviewed by an independent Safety Monitoring Board. Description of microbiological techniques is provided. To the best of our knowledge, this is the first published protocol that aims to establish a standardised, individualised phage-treatment framework for intestinal decolonisation in a high-endemic setting. It will also explore phage-bacterial interactions and their broader impact on bacterial virulence and susceptibility profiles. It represents a stepping stone towards implementing phage therapy in South America and bringing knowledge and capacities to the countries most impacted by escalating antimicrobial resistance.

1 December 2022 in Annals of Internal Medicine: Clinical Cases
Verified
Journal Article
Open access
Iris NajjarIris Najjar
Iris Najjar
GKGatete Karege
Gatete Karege
HRHelia Robert-Ebadi
Helia Robert-Ebadi
Formerly known as “trench foot” or “immersion foot,” nonfreezing cold injury (NFCI) is a rare condition mainly seen among vulnerable groups. We report the case of a homeless male diagnosed with NFC...